Trial reportJACC. Cardiovascular imaging2015
Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization.
Trial report in JACC. Cardiovascular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00023595 (Surgical Treatment for Ischemic Heart Failure), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surgical Treatment for Ischemic Heart Failure (STICH)
Who cites it
21 citing papers in PubMed, 70 citations in OpenAlex.
- Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.The New England journal of medicine · 2019Trial
- Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.European journal of heart failure · 2019Trial
- Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.The New England journal of medicine · 2016Trial
- Predict value of ratio of hibernating myocardium in TPD on reverse remodeling and MACEs in HFrEF patients post-revascularization.The international journal of cardiovascular imaging · 2025Article
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How.Journal of the American Heart Association · 2023Review
- Concomitant Mitral Valve Surgery Versus No Intervention in Patients with Moderate Ischemic Mitral Regurgitation Undergoing Coronary Artery Bypass Grafting: A Propensity Score Analysis.Juntendo Iji zasshi = Juntendo medical journal · 2023Article
- Myocardial Viability Testing in the Management of Ischemic Heart Failure.Life (Basel, Switzerland) · 2022Review
- Left ventricular volume change and long-term outcomes in ischaemic cardiomyopathy with or without surgical revascularisation: A post-hoc analysis of a randomised controlled trial.EClinicalMedicine · 2022Article
- Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy.Clinical cardiology · 2022Review
- Non-transmural myocardial infarction associated with regional contractile function is an independent predictor of positive outcome: an integrated approach to myocardial viability.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2021Article
- Long-term outcomes of autologous skeletal myoblast cell-sheet transplantation for end-stage ischemic cardiomyopathy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Coronary Revascularization in Patients With Stable Coronary Artery Disease: The Role of Imaging.Frontiers in cardiovascular medicine · 2021Review
- Low dose wall motion score predicts the short and long-term benefit of surgical revascularization in patients with ischemic left ventricular dysfunction.The international journal of cardiovascular imaging · 2019Article
- Jeopardized Myocardium Defined by Late Gadolinium Enhancement Magnetic Resonance Imaging Predicts Survival in Patients With Ischemic Cardiomyopathy: Impact of Revascularization.Journal of the American Heart Association · 2018Article
- Imaging the myocardial ischemic cascade.The international journal of cardiovascular imaging · 2018Review
- Cardiac death in patients with left ventricular aneurysm, remodeling and myocardial viability by gatedThe international journal of cardiovascular imaging · 2018Article
- The Role for Cardiovascular Remodeling in Cardiovascular Outcomes.Current atherosclerosis reports · 2017Review
- Cardiac surgery 2015 reviewed.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Review
- Myocardial Viability and Revascularization: Current Understanding and Future Directions.Current atherosclerosis reports · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 16 institutions in 7 countries.
Funding
Abstract
objectivesThis study sought to test the hypothesis that end-systolic volume (ESV), as a marker of severity of left ventricular (LV) remodeling, influences the relationship between myocardial viability and survival in patients with coronary artery disease and LV systolic dysfunction.
backgroundRetrospective studies of ischemic LV dysfunction suggest that the severity of LV remodeling determines whether myocardial viability predicts improved survival with surgical compared with medical therapy, with coronary artery bypass grafting (CABG) only benefitting patients with viable myocardium who have smaller ESV. However, this has not been tested prospectively.
methodsInteractions of end-systolic volume index (ESVI), myocardial viability, and treatment with respect to survival were assessed in patients in the prospective randomized STICH (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease) trial of CABG versus medical therapy who underwent viability assessment (n = 601; age 61 ± 9 years; ejection fraction ≤35%), with a median follow-up of 5.1 years. Median ESVI was 84 ml/m(2). Viability was assessed by single-photon emission computed tomography or dobutamine echocardiography using pre-specified criteria.
resultsMortality was highest among patients with larger ESVI and nonviability (p < 0.001), but no interaction was observed between ESVI, viability status, and treatment assignment (p = 0.491). Specifically, the effect of CABG versus medical therapy in patients with viable myocardium and ESVI ≤84 ml/m(2) (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.56 to 1.29) was no different than in patients with viability and ESVI >84 ml/m(2) (HR: 0.87; 95% CI: 0.57 to 1.31). Other ESVI thresholds yielded similar results, including ESVI ≤60 ml/m(2) (HR: 0.87; 95% CI: 0.44 to 1.74). ESVI and viability assessed as continuous rather than dichotomous variables yielded similar results (p = 0.562).
conclusionsAmong patients with ischemic cardiomyopathy, those with greater LV ESVI and no substantial viability had worse prognosis. However, the effect of CABG relative to medical therapy was not differentially influenced by the combination of these 2 factors. Lower ESVI did not identify patients in whom myocardial viability predicted better outcome with CABG relative to medical therapy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.